Sociedad Americana de Hirudoterapia

Milestones & Timeline

Our trajectory from founding to institution-building

Última actualización: March 18, 2026Revisado por: ASH Editorial Board
501(c)(3) Tax-Exempt Organization·EIN: 92-2997844

Organizational Timeline

The American Society of Hirudotherapy was founded in 2024 to fill a critical gap: the absence of an independent, evidence-based professional organization for hirudotherapy in the United States. Below is a timeline of key milestones in our development and in the broader regulatory environment that shapes our work.

Regulatory Milestones

2004

FDA 510(k) Clearance — Ricarimpex SAS

The FDA clears medicinal leeches (Hirudo medicinalis) as a medical device via 510(k) K040187, establishing the U.S. regulatory framework for hirudotherapy. Product code NRN assigned.

2014

510(k) Clearance — Biopharm Leeches

Biopharm receives 510(k) clearance (K132958) for medicinal leeches, expanding the supply chain for FDA-cleared leeches in the U.S.

2015

510(k) Clearance — Carolina Biological

Carolina Biological Supply Company receives 510(k) clearance (K140907), further diversifying the cleared supply chain.

2024 Dec

CBER Transfer

Effective December 30, 2024, regulatory oversight of medicinal leeches transfers from CDRH to CBER (Center for Biologics Evaluation and Research) per Federal Register notice.

ASH Milestones

2024

Organization Founded

American Society of Hirudotherapy, Inc. established in California. 501(c)(3) tax-exempt status obtained (EIN 92-2997844). Mission defined: evidence-based education, safety standards, and supply chain integrity for hirudotherapy.

2025 Q1

Website Launch

Launch of hirudotherapysociety.org with peer-reviewed clinical evidence reviews, leech biology reference library, safety protocols, and regulatory guidance. Initial content: 60+ evidence-based pages.

2025 Q2–Q4

Content Expansion

Expansion to 150+ evidence-based pages covering clinical conditions, leech biology, aquaculture, pharmacology, and regulatory frameworks. Research article library with 31 indexed studies.

2025–2026

Advisory Board Formation

Recruitment of clinical and scientific advisors across six disciplines: plastic surgery, vascular medicine, infectious disease, regulatory affairs, bioethics, and aquaculture science.

2026

Governance Hardening

Implementation of institutional-grade governance framework: conflict-of-interest policies, financial transparency, FDA compliance linting, and investor-readiness infrastructure.

Planned Initiatives

Continuing Medical Education (CME) Pathway

Development of accredited CME modules for physicians and advanced practice clinicians.

Research Grant Program

Establishment of a small grants program to fund pilot studies in hirudotherapy.

Aquaculture Facility

Development of a controlled-environment aquaculture facility for medical-grade leech production in Stanton, California.

National Conference

Planning for the first annual ASH national conference for practitioners, researchers, and stakeholders.

Recursos relacionados

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.